--- title: "Big Pharma Bets on India: How Global Drugmakers Are Transforming Clinical Trials Strategy" description: "Takeda eyes India for global clinical trials as AI-led R&D expands. Lower costs, faster recruitment and improved regulation position India as a pharma R&D hub." author: Darie Nani (Editor-in-Chief) date: 2025-08-24T09:46:37.000Z updated: 2026-03-31T13:20:02.312Z canonical: https://www.sovereignmagazine.com/article/big-pharma-bets-on-india-how-global-drugmakers-are-transforming-clinical-trials-strategy image: https://cdn.nanimediahouse.com/6132245.jpeg categories: Science & Tech content_type: News region: Bangalore publication: Sovereign Magazine --- Japanese pharmaceutical giant [Takeda is exploring India for global clinical trials](https://www.reuters.com/business/healthcare-pharmaceuticals/japans-takeda-weighs-india-global-trials-speed-up-drug-launches-2025-08-21/) to accelerate the launch of its drugs in the world’s most populous nation. This development signals India’s evolution from the ‘pharmacy of the world’ to a comprehensive R&D partner for global drugmakers. The move by Takeda, which operates an [innovation centre in Bengaluru focused on AI and data science](https://www.reuters.com/business/healthcare-pharmaceuticals/japans-takeda-weighs-india-global-trials-speed-up-drug-launches-2025-08-21/), reflects a broader industry recognition of India’s advantages beyond traditional manufacturing. The country’s clinical trial market, valued at [$1.42 billion in 2024](https://www.grandviewresearch.com/industry-analysis/india-clinical-trials-market), is projected to grow at 8% annually through 2030. ## The Economic Advantage India’s transition from manufacturing hub to R&D powerhouse revolves around compelling economics and operational advantages. Clinical trials in India cost [50-60% less than in Western countries](https://credevo.com/articles/2024/02/15/top-8-reasons-to-choose-india-as-your-clinical-trial-destination-advantages-and-strategic-benefits/), while Indian clinical sites demonstrate superior performance with 85% meeting or exceeding recruitment targets compared to 65% globally. The country’s 1.4 billion population provides access to genetically diverse patient groups across a wide spectrum of diseases, addressing pharmaceutical companies’ need for representative trial data to meet global regulatory requirements. This diversity proves particularly valuable for trials in oncology, neuroscience and rare disorders, similar to advances in [personalised medicine using population-specific data](https://www.sovereignmagazine.com/article/personalised-medicine-without-borders-biostate-ai-s-data-first-expansion-challenges-tunnel-vi). Regulatory improvements by India’s Central Drugs Standard Control Organisation (CDSCO) have streamlined approval processes, with [updated clinical trial guidelines released in April 2024](https://thehealthmaster.com/2024/04/16/cdsco-releases-draft-guidelines-for-clinical-trial-in-india/) enhancing compliance with international Good Clinical Practice standards. ## Research Integration Expansion Takeda’s plans extend beyond cost savings to deeper integration with India’s research capabilities. ‘Our eventual aim is to integrate India’s research and development ecosystem into our global pipeline and expand Indian patients’ access to cutting-edge therapies in oncology, neuroscience, gastrointestinal health, and inflammation,’ Annapurna Das, general manager of Takeda’s India operations, told Reuters. The company is exploring partnerships with local academia, healthcare providers and technology firms, following a pattern established by other global pharmaceutical companies leveraging India’s [integrated CRDMO India](https://www.sailife.com/) capabilities for comprehensive drug development services. This shift mirrors broader trends in [digital platforms reshaping drug development](https://www.sovereignmagazine.com/article/digital-platforms-reshape-patient-led-drug-development-as-rare-disease-market-approaches-200-) globally. India’s pharmaceutical sector is positioning itself for explosive growth, with the market projected to reach [$65 billion in 2024 and $130 billion by 2030](https://www.ibef.org/industry/pharmaceutical-india). A recent EY-Parthenon report found that [79% of pharmaceutical leaders emphasise AI and machine learning adoption](https://www.ey.com/en_in/newsroom/2024/11/india-s-pharma-sector-set-for-explosive-growth-79-percent-cxo-s-see-ai-ml-as-key-86-percent-call-for-ecosystem-collaboration-ey-parthenon-oppi-report) in drug discovery and clinical development. ## Industry-Wide Transformation The trend towards India as an R&D destination extends beyond individual company strategies. The country now hosts over [650 US FDA-approved manufacturing sites](https://www.ibef.org/industry/pharmaceutical-india), providing a robust foundation for clinical trial infrastructure. Recent regulatory certifications further enhance India’s credibility as a global pharmaceutical partner. Contract manufacturer Akums received [ANVISA GMP certification for its sterile manufacturing plant](https://www.theglobeandmail.com/investing/markets/markets-news/Newsfile/34300975/akums-receives-anvisa-gmp-certification-for-sterile-manufacturing-plant-expands-global-sterile-manufacturing-footprint/) in August, expanding its global manufacturing footprint and demonstrating Indian companies’ ability to meet stringent international standards. Phase III trials currently dominate 53.3% of India’s clinical trials market share, reflecting the country’s capacity for large-scale trials with diverse patient demographics. This capability particularly benefits pharmaceutical companies developing treatments for oncology, autoimmune diseases and rare disorders, areas where [genetic data collection raises important questions](https://www.sovereignmagazine.com/article/genetic-data-acquisition-raises-critical-questions-for-healthcare-innovation) about privacy and research ethics. ### Accelerating Time-to-Market The combination of cost efficiency, rapid patient recruitment and improved regulatory frameworks positions India as a key resource for global pharmaceutical companies seeking to accelerate drug development timelines. Industry analysts predict this trend will reshape how new therapies reach patients worldwide, with India serving as a critical link between drug discovery and [global market access](https://www.sovereignmagazine.com/article/patent-games-how-big-pharma-uses-new-drug-forms-to-beat-the-generic-clock). As pharmaceutical companies face increasing pressure to reduce R&D costs while maintaining development quality, India’s integrated network offers a compelling solution that extends far beyond traditional manufacturing outsourcing to encompass the entire drug development lifecycle.